Valeant raises cash-stock offer for Allergan (Update)

May 28, 2014 by Tom Murphy
This March 20, 2002 file photo shows a vial of Botox, made by Allergan. Valeant Pharmaceuticals has pumped more cash into its bid to buy Allergan, and it also defended its business model on Wednesday, May 28, 2014, a day after its reluctant acquisition target aired more concerns about a deal. (AP Photo/Damian Dovarganes, File)

Valeant Pharmaceuticals has pumped more cash into its bid for Botox maker Allergan, and it also defended its business model on Wednesday, a day after its reluctant acquisition target aired more concerns about a deal.

The Canadian drugmaker said it will now offer $58.30 and a portion of its stock for each Allergan share. The revised bid could be worth more than $50 billion, based on Tuesday's closing price for U.S.-traded shares of Valeant. But it still may not be enough to get Allergan to the negotiating table, analysts say.

Valeant Pharmaceuticals International Inc. also threw in a contingent value right worth up to $25 per share and based on future sales of a potential eye treatment.

Valeant raised the cash portion of its offer by $10 from a previous bid of $48.30 per share. That was part of an unsolicited offer rejected by Allergan that was worth nearly $46 billion when Valeant announced it last month.

Allergan Inc. said in a brief statement Wednesday that it would carefully review the new proposal.

Valeant Chairman and CEO J. Michael Pearson told investors in a Wednesday morning webcast that he had talked to many Allergan stock owners "and the real message we continually got back is Allergan shareholders want this deal to occur, but they wanted a higher price."

That price still may not be high enough for investors. Shares of both companies fell Wednesday while broader trading indexes were largely flat.

The latest bid totals about $166 in cash and stock for each Allergan share, and shareholders may be looking for something in the $180 range, Credit Suisse analyst Dr. Vamil Divan said in a research note.

Allergan, which also makes the dry eye treatment Restasis, has said repeatedly that it opposes a deal with Valeant. Shortly after Valeant made its offer public, Allergan announced a so-called poison pill plan, a defensive tactic that makes a buyout prohibitively expensive. Earlier this month, Allergan said that Valeant's uncertain long-term growth prospects and business model create a risk for Allergan shareholders, given the stock component of the offer.

On Tuesday, it questioned Valeant's ability to deliver organic growth, which doesn't count gains through acquisition. It also said in a statement that the Canadian drugmaker has limited experience with "large, global scale products" and would cut research and development costs too much.

Citi analyst Liav Abraham said in a research note that said she doesn't expect the latest Valeant offer to bring Allergan to the negotiating table for a friendly transaction. She has low expectations for the eye treatment involved in the contingent value right, and she predicts that Valeant will take its bid hostile and go directly to Allergan shareholders after the company rejects the latest overture.

Valeant made its initial bid along with activist investor Bill Ackman. The investor's Pershing Square Capital Management LP holds a 9.7 percent stake in Allergan. Pershing had agreed to take only stock if the deal went through and would remain as a long-term shareholder of the combined company.

Valeant Chairman and CEO J. Michael Pearson said Wednesday in a letter to his Allergan counterpart, David Pyott, that the two sides should meet.

"It appears based on Allergan's recent public statements that you have a fundamental misunderstanding of our business model and its performance," Pearson wrote.

Valeant also said that Allergan's analysis of its business "was full of errors," and its operating model would speed up growth for Allergan products, especially in developing markets.

Pearson also touted the performance of several Valeant executives during his presentation to investors, although he acknowledged he couldn't pronounce some of their last names.

Separately, Nestle said Wednesday that it will pay $1.4 billion in cash to Valeant for the rights to sell lip and wrinkle treatment Restylane and other skin products in the U.S. and Canada.

Valeant completed an $8.7 billion acquisition of contact lens maker Bausch + Lomb last year. Its latest deal comes amid a surge of pharmaceutical bids, as drugmakers seek to grow or ditch assets that aren't central to their business.

The Valeant-Allergan saga is one of several multibillion-dollar acquisition stories the drug industry has seen so far this year.

British drugmaker AstraZeneca rejected several takeover offers from U.S. counterpart Pfizer, the latest being a nearly $119 billion deal that would have amounted to the richest acquisition ever among drugmakers. Switzerland's Novartis AG has agreed to buy GlaxoSmithKline's cancer-drug business for up to $16 billion, while selling most of its vaccines business to GSK for $7.1 billion, plus royalties.

Shares of Irvine, California-based Allergan fell 4.4 percent, or $7.27, to $157.75 Wednesday afternoon, and U.S.-traded shares of Valeant dropped $1.95 to $128.

Explore further: Valeant Pharma plans improved offer for Allergan

Related Stories

Valeant Pharma plans improved offer for Allergan

May 13, 2014
Valeant Pharmaceuticals will not easily accept rejection in its bid to acquire Botox maker Allergan for nearly $46 billion.

Allergan board turns down Valeant takeover offer (Update)

May 12, 2014
Botox maker Allergan formally rejected on Monday a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited offer worth nearly $46 billion undervalues the company and poses a significant risk to its growth prospects.

Valeant, Ackman make $45.6B Allergan bid

April 22, 2014
Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

Botox maker Allergan draws bid from Valeant (Update)

April 21, 2014
Valeant Pharmaceuticals is teaming up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.

Valeant agrees to pay about $2.6B for Medicis

September 3, 2012
(AP)—Valeant Pharmaceuticals International Inc. has agreed to buy dermatology products maker Medicis Pharmaceutical Corp. for about $2.6 billion in cash in a deal to strengthen its position in skin treatments and care.

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.